title: μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief.
abstract: BACKGROUND
  The perception that smoking relieves negative affect contributes to smoking persistence. Endogenous opioid neurotransmission, and the μ-opioid receptor (MOR) in particular, plays a role in affective regulation and is modulated by nicotine.
  
  
  OBJECTIVE
  We examined the relationship of MOR binding availability in the amygdala to the motivation to smoke for negative affect relief and to the acute effects of smoking on affective responses.
  
  
  METHODS
  Twenty-two smokers were scanned on two separate occasions after overnight abstinence using [¹¹C]carfentanil positron emission tomography imaging: after smoking a nicotine-containing cigarette and after smoking a denicotinized cigarette. Self-reports of smoking motives were collected at baseline, and measures of positive and negative affect were collected pre- and post- cigarette smoking.
  
  
  RESULTS
  Higher MOR availability in the amygdala was associated with motivation to smoke to relieve negative affect. However, MOR availability was unrelated to changes in affect after smoking either cigarette.
  
  
  CONCLUSIONS
  Increased MOR availability in amygdala may underlie the motivation to smoke for negative affective relief. These results are consistent with previous data highlighting the role of MOR neurotransmission in smoking behavior.
authors.affiliation: Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Mary
authors.initials: M
authors.lastname: Falcone
authors.forename: Allison B
authors.initials: AB
authors.lastname: Gold
authors.forename: E Paul
authors.initials: EP
authors.lastname: Wileyto
authors.forename: Riju
authors.initials: R
authors.lastname: Ray
authors.forename: Kosha
authors.initials: K
authors.lastname: Ruparel
authors.forename: Andrew
authors.initials: A
authors.lastname: Newberg
authors.forename: Jacob
authors.initials: J
authors.lastname: Dubroff
authors.forename: Jean
authors.initials: J
authors.lastname: Logan
authors.forename: Jon-Kar
authors.initials: JK
authors.lastname: Zubieta
authors.forename: Julie A
authors.initials: JA
authors.lastname: Blendy
authors.forename: Caryn
authors.initials: C
authors.lastname: Lerman
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects / Q000502:physiology*; D000679:Amygdala / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D002250:Carbon Radioisotopes; D004311:Double-Blind Method; D005260:Female; D005283:Fentanyl / Q000031:analogs & derivatives; D059907:Functional Neuroimaging / Q000379:methods / Q000523:psychology*; D006801:Humans; D008297:Male; D009042:Motivation / Q000502:physiology; D009538:Nicotine / Q000494:pharmacology; D049268:Positron-Emission Tomography / Q000379:methods / Q000523:psychology; D011869:Radioligand Assay / Q000379:methods / Q000523:psychology; D017450:Receptors, Opioid, mu / Q000378:metabolism / Q000502:physiology*; D012907:Smoking / Q000503:physiopathology* / Q000523:psychology*
chemical_list: D002250:Carbon Radioisotopes; D017450:Receptors, Opioid, mu; D009538:Nicotine; C017114:carfentanil; D005283:Fentanyl